Amphion Innovations PLC Additional Draw Down on Loan Facility (9973D)
July 13 2016 - 2:00AM
UK Regulatory
TIDMAMP
RNS Number : 9973D
Amphion Innovations PLC
13 July 2016
Amphion Innovations plc
("Amphion" or "the Company")
Additional Draw Down on Loan Facility
London and New York, 13 July 2016 - Amphion Innovations plc
(AIM: AMP), the developer of medical, life science, and technology
businesses, today announces that the Company has agreed terms for
the draw-down of an additional tranche of US $750,000 (an
"Additional Draw") under the loan facility as initially announced
on 5 June 2014 (the "Facility"). The Company will receive the
proceeds of the Additional Draw immediately.
Under the terms of the Additional Draw, nil interest is charged
with a repayment amount of US $881,250 due on 6 October 2016. The
proceeds of the Additional Draw are to be used to partially repay
the existing amount due under the Facility and for working capital
for Amphion and its Partner Companies. The Additional Draw may be
converted into Ordinary Shares in Amphion in accordance with the
additional terms of the Facility announced on 29 April 2016.
The Additional Draw is to be secured by the Company pledging an
additional amount of marketable securities, equivalent in value to
US $900,000, within 30 days of this announcement.
For further information please contact:
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate
Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 3861 6625
Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and
technology businesses.
We use our extensive experience in company building to invest
and build shareholder value in high growth companies in the US and
UK. Amphion has significant shareholding in 7 Partner Companies
developing proven technologies targeting substantial commercial
marketplaces. The Amphion model has been refined to optimise the
commercialisation of patents and other intellectual property within
the Partner Companies. The Partner Companies collectively own or
control over 200 separately identified pieces of intellectual
property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLGDRRXBBGLD
(END) Dow Jones Newswires
July 13, 2016 02:00 ET (06:00 GMT)
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2023 to Apr 2024